Valeant Inks $1B Deal For Female Libido Drugmaker Sprout

Law360, New York (August 20, 2015, 8:25 AM EDT) -- Valeant Pharmaceuticals International Inc. will shell out $1 billion in cash for Sprout Pharmaceuticals Inc., snapping up the drugmaker that recently gained approval for its female libido pill, the two companies said Thursday.

The announcement comes just two days after the U.S. Food and Drug Administration gave a go-ahead to Sprout’s drug flibanserin, the first approved drug to treat low sexual desire in premenopausal women, amid controversy among scientists skeptical of its benefits and women’s rights groups seeking parity in sexual health treatments.  The drug will be marketed in the U.S. under the brand name Addyi.

“Delivering a first-ever treatment for...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!